These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33486671)

  • 21. Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
    Axelsson M; Dubuisson N; Novakova L; Malmeström C; Giovannoni G; Lycke J; Gnanapavan S
    Acta Neurol Scand; 2019 May; 139(5):422-427. PubMed ID: 30657162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High levels of cerebrospinal fluid IgM binding to myelin basic protein are associated with early benign course in multiple sclerosis.
    Annunziata P; Pluchino S; Martino T; Guazzi G
    J Neuroimmunol; 1997 Jul; 77(1):128-33. PubMed ID: 9209277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis.
    Callea L; Arese M; Orlandini A; Bargnani C; Priori A; Bussolino F
    J Neuroimmunol; 1999 Feb; 94(1-2):212-21. PubMed ID: 10376955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.
    Rossi S; Studer V; Motta C; Germani G; Macchiarulo G; Buttari F; Mancino R; Castelli M; De Chiara V; Weiss S; Martino G; Furlan R; Centonze D
    J Neuroinflammation; 2014 Feb; 11():32. PubMed ID: 24548694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.
    Regenold WT; Phatak P; Makley MJ; Stone RD; Kling MA
    J Neurol Sci; 2008 Dec; 275(1-2):106-12. PubMed ID: 18783801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.
    Klawiter EC; Piccio L; Lyons JA; Mikesell R; O'Connor KC; Cross AH
    Arch Neurol; 2010 Sep; 67(9):1102-8. PubMed ID: 20837855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis.
    Di Filippo M; Pini LA; Pelliccioli GP; Calabresi P; Sarchielli P
    J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1224-9. PubMed ID: 18535023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
    J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study.
    Olesen MN; Soelberg K; Debrabant B; Nilsson AC; Lillevang ST; Grauslund J; Brandslund I; Madsen JS; Paul F; Smith TJ; Jarius S; Asgari N
    J Neuroinflammation; 2019 Mar; 16(1):59. PubMed ID: 30857557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis.
    Akaishi T; Takahashi T; Fujihara K; Misu T; Nishiyama S; Takai Y; Fujimori J; Abe M; Ishii T; Aoki M; Nakashima I
    Mult Scler Relat Disord; 2020 Oct; 45():102382. PubMed ID: 32674030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated CSF concentration of CCL3 and CCL4 in relapsing remitting multiple sclerosis patients.
    Soleimani M; Soleymani A; Seyyedirad N
    J Immunoassay Immunochem; 2019; 40(4):378-385. PubMed ID: 31268406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains.
    Rudick RA; Medendorp SV; Namey M; Boyle S; Fischer J
    Mult Scler; 1995 Nov; 1(3):150-5. PubMed ID: 9345445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules.
    Fainardi E; Granieri E; Tola MR; Melchiorri L; Vaghi L; Rizzo R; Castellazzi M; Ceruti S; Paolino E; Baricordi OR
    J Neuroimmunol; 2002 Dec; 133(1-2):151-9. PubMed ID: 12446018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Cerebrospinal Fluid Balance of TNF and TNF Receptors in Naïve Multiple Sclerosis Patients: Early Involvement in Compartmentalised Intrathecal Inflammation.
    Magliozzi R; Pezzini F; Pucci M; Rossi S; Facchiano F; Marastoni D; Montagnana M; Lippi G; Reynolds R; Calabrese M
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.
    Rathbone E; Durant L; Kinsella J; Parker AR; Hassan-Smith G; Douglas MR; Curnow SJ
    J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1044-1049. PubMed ID: 29743290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum.
    Kusminski CM; McTernan PG; Schraw T; Kos K; O'Hare JP; Ahima R; Kumar S; Scherer PE
    Diabetologia; 2007 Mar; 50(3):634-42. PubMed ID: 17242917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
    Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
    J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.